White matter disease: Targeted aspartoacylase gene therapy reverts Canavan disease – Nature.com
Nature.com |
White matter disease: Targeted aspartoacylase gene therapy reverts Canavan disease
Nature.com On the basis of these findings, the researchers designed a gene therapy approach to specifically deliver functional ASPA to oligodendrocytes. “Our approach employed somatic gene transfer using recombinant adeno-associated virus (AAV),” comments … |
